Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Indivior PLC on Thursday reported a swing to a full-year loss due to a provision for litigation, despite net revenue jumping by 14% due to growth in its Sublocade injection.
Shares were down 12% at 1,719 pence each on Thursday morning in London.
The Richmond, Virginia-based pharmaceutical firm swung to a pretax loss of $95 million in 2022 from a profit of $190 million in 2021, despite a jump by 14% in net revenue to $901 million from $791 million.
Indivior booked a $290 million exceptional provision in 2021, as it navigates initial mediation sessions in late January regarding legacy civil multi-district antitrust litigation.
‘Because these matters are in various stages, Indivior cannot predict with any certainty how these matters will ultimately be resolved, or the costs, or timing of such resolution. In particular, any final aggregate costs of these matters, whether resolved by settlement or trial, may be materially different from this provision,’ the company said.
Operating loss was $85 million in 2022, compared to a profit of $213 million the year before. However, on an adjusted basis, operating profit rose by 13% to $212 million from $187 million.
In the fourth quarter alone, net revenue amounted to $241 million, up from $222 million a year earlier. Indivior swung to a pretax loss of $256 million in the quarter, from a profit of $39 million a year before, though adjusted operating profit rose by 25% to $40 million form $32 million.
The company said the net revenue growth was primarily driven by Sublocade.
Chief Executive Officer Mark Crossley said: ‘I am pleased to report another strong year of execution against our strategic priorities, resulting in double-digit underlying growth across our key financial metrics.’
Looking ahead, Indivior expects net revenue for 2023 to be in the range of $950 million to $1.02 billion, reflecting strong growth in Perseris and Sublocade.
Perseris is an extended-release injection for schizophrenia, while Sublocade is buprenorphine extended-release injection for opioid addiction, both of which are long-acting injectable products
Copyright 2023 Alliance News Ltd. All Rights Reserved.